Serotonergic modulation of visceral sensation: Lower gut

Gut

Volumn 51, Issue SUPPL. 1, 2002, Pages

  Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLECARBOXYLIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; ALOSETRON; BUSPIRONE; CILANSETRON; CITALOPRAM; DESIPRAMINE; FLUPHENAZINE; NORTRIPTYLINE; PRUCALOPRIDE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; TEGASEROD;

ABDOMINAL PAIN; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; GENDER; HUMAN; IRRITABLE COLON; NEUROMODULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SEROTONINERGIC SYSTEM; SIDE EFFECT;

EID: 0036288117     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.51.suppl_1.i81     Document Type: Conference Paper

References (53)

1. Serotonin: A mediator of the brain-gut connection
2. Guinea pig 5-HT transporter: Cloning, expression, distribution, and function in intestinal sensory reception
3. Irritable bowel syndrome: A technical review For practice guideline development
4. Antidepressants For functional gastrointestinal syndromes
5. Fluoxetine
6. Buspirone: Future directions
7. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug
8. Buspirone inhibits corticotropin-releasing factor and stress-induced cecal motor response in rats by acting through 5-HT1A receptors
9. Antidepressants in depressed patients with irritable bowel syndrome
10. Pharmacokinetics of selective serotonin reuptake inhibitors
11. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding
12. 5-Hydroxytryptamine and human small intestinal motility: Effect of inhibiting 5-hydroxytryptamine reuptake
13. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome
14. Irritable colon and depression
15. Psychological significance of the irritable colon syndrome
16. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity
17. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans
18. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia
19. The effect of trimipramine in patients with the irritable bowel syndrome
20. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome
21. Effects of desipramine on IBS compared with atropine and placebo
22. Comparison of various treatments for irritable bowel syndrome
23. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
24. Vagal afferent-mediated inhibition of a nociceptive reflex by i.v. serotonin in the rat. II. Role of 5-HT receptor subtypes
25. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat
26. 3 receptors on spinal primary afferents projecting to the colon of the rat - A peripheral target for alosetron
27. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans
28. 3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea
29. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
30. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
31. Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome (D-IBS)
32. 3 antagonist, alosetron, on basal and cholera toxin-induced secretion in the human jejunum: A segmental perfusion study
33. 3-receptor antagonist
34. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
35. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
36. A randomized controlled clinical trial of the serotonin type 3 receptor antagoinist alosetron in women with diarrhea predominant irritable bowel syndrome
37. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
38. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
39. SDZ HTF 919 stimulates colonic motility and transit in vivo
40. 4 receptor partial agonist, on colorectal distension in rats
41. 4 receptor agonist
42. 4 receptor partial agonist, accelerates gastrointestinal transit
43. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
44. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
45. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome
46. Review article: Tegaserod
47. 4 receptors mediate the R093877-induced changes in contractile patterns in the canine colon
48. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers
49. 4 agonist, prucalopride, in healthy humans
50. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
51. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: Results of two double-blind, placebo-controlled trials
52. The efficacy and safety of prucalopride in patients with chronic constipation
53. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man